Spyre Therapeutics, Inc. advances SPY001 into next trial phase after meeting primary endpoint

Traders Union
All News
Companies
Spyre SPY001 Phase 2 success

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Billionaires

Companies

Regulators News

Yaroslav Dmytrenko

13.04.2026

Spyre Therapeutics, Inc. advances SPY001 into next trial phase after meeting primary endpoint — Spyre SPY001 Phase 2 success

Spyre Therapeutics, Inc. announced positive results from the Part A segment of its Phase 2 clinical trial of SPY001 in patients with ulcerative colitis.

The company reported that SPY001 reached its primary endpoint and was well tolerated. Following these promising outcomes, Spyre Therapeutics, Inc. will proceed with Part B of the trial, which will examine the effectiveness of monotherapies and combination therapies across its platform.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Spyre Therapeutics, Inc. recently completed patient recruitment for the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial, with topline results expected in the third quarter of 2026, according to a previous announcement. The company also held its annual event where employees assembled 1,500 student kits and organized a physician IBD panel, as noted in a company update. These developments reflect Spyre’s ongoing research activities and community engagement alongside its clinical trial progress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Crypto on the court: How NBA Finals became a showcase for Ledger

By Anastasiia Chabaniuk
Yesterday

Crypto on the court: How NBA Finals became a showcase for Ledger

Editors' Picks

How to build wealth from scratch in 3 practical steps

By Johnathan Maverick
Yesterday

How to build wealth from scratch in 3 practical steps

Editors' Picks

Kospi Index crash: Why South Korean market fell alongside AI stocks

By Eugene Komchuk
08.06.2026

Kospi Index crash: Why South Korean market fell alongside AI stocks

Editors' Picks

All Editors' Top Picks

Latest Spyre News

Paul Fehlner joins Spyre Therapeutics, Inc. as Chief IP Counsel with science and law expertise

By Ashutosh Sureka
16 hours ago

Paul Fehlner joins Spyre Therapeutics, Inc. as Chief IP Counsel with science and law expertise

Companies

Spyre Therapeutics, Inc. secures spot on 2026 IncBestWorkplaces list for dynamic team culture

By Artem Shendetskii
05.06.2026

Spyre Therapeutics, Inc. secures spot on 2026 IncBestWorkplaces list for dynamic team culture

Companies

Spyre Therapeutics, Inc. advances new therapies for ulcerative colitis and Crohns disease

By Olga Shendetskaya
20.05.2026

Spyre Therapeutics, Inc. advances new therapies for ulcerative colitis and Crohns disease

Companies

Anastasiia Chabaniuk
Yesterday

Crypto on the court: How NBA Finals became a showcase for Ledger

Johnathan Maverick
Yesterday

How to build wealth from scratch in 3 practical steps

Eugene Komchuk
08.06.2026

Kospi Index crash: Why South Korean market fell alongside AI stocks

Mira Kyivska
07.06.2026

Bitcoin or Ferrari: Which investment is better?

Mira Kyivska
06.06.2026

Strategy sells Bitcoin: Small sale tests market confidence

Hanna Syniavska
35 min ago

Gregory Raymond: 93 percent of leaders want AI agents but only 2 percent succeed due to payments

Daria Chernytska
35 min ago

Tokenisation offers new potential for film industry, Jean-Michel Pailhon notes

Yaroslav Dmytrenko
51 min ago

Self-custody and custodial wallets serve distinct roles, Henri Arslanian notes

Elena Nikulina
2 hours ago

Stock markets show signs of cooling off despite AI interest, Jason Pizzino notes

Andrey Mastykin
2 hours ago

AI and war drive factory price gap in China, Christophe Barraud notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Anastasiia Chabaniuk
28 min ago

Trump family made $2.3B from crypto ventures as investors faced losses

Trump family made $2.3B from crypto ventures as investors faced losses

Olga Shendetskaya
47 min ago

U.S. strikes on Iran weigh on Wall Street

U.S. strikes on Iran weigh on Wall Street

Eugene Komchuk
1 hour ago

Oil jumps to $93 after U.S. and Iran exchange strikes

Oil jumps to $93 after U.S. and Iran exchange strikes

Igor Krasulya
16 hours ago

SpaceX-Google pact fuels debate over IPO valuation

SpaceX-Google pact fuels debate over IPO valuation

Jose Antonio Gastelum
20 hours ago

U.S. futures rise as AI IPO hopes lift tech sentiment

U.S. futures rise as AI IPO hopes lift tech sentiment

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

Crypto winter fears return as Bitcoin faces risk of 40% decline

Dmytro Kharkov
Now

IBM seeks fresh momentum after four-day losing streak

Anton Kharitonov
Now

Microsoft declines as market seeks returns on AI investments

Anton Kharitonov
Now

Apple declines after WWDC as investors expected more

Dmytro Kharkov
Now

Intel gains momentum as Google and Nvidia fuel foundry hopes

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.